Literature DB >> 26454420

Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.

Aline Daniele Furlan Pagliotto1, Katiany Rizzieri Caleffi-Ferracioli2, Mariana Aparecida Lopes3, Vanessa Pietrowski Baldin3, Clarice Queico Fujimura Leite4, Fernando Rogério Pavan4, Regiane Bertin de Lima Scodro2, Vera Lúcia Dias Siqueira2, Rosilene Fressatti Cardoso5.   

Abstract

We report the in vitro drugs interaction by the resazurin drugs combination microtiter assay (REDCA) of amoxicillin (AMO)/clavulanate (CLAV) with isoniazid (INH), ethambutol (EMB), and rifampicin (RIF) against susceptible and resistant Mycobacterium tuberculosis isolates. The addition of AMO/CLAV to classical antituberculosis drugs should be explored as a promising alternative for the treatment of resistant tuberculosis (TB).
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Mycobacterium tuberculosis; amoxicillin/clavulanate; checkerboard; synergism; tuberculosis

Mesh：

Substances：

Year:  2015        PMID： 26454420     DOI： 10.1016/j.jmii.2015.08.025

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN： 1684-1182            Impact factor:   4.399


  7 in total

1.  Revisiting the β-Lactams for Tuberculosis Therapy with a Compound-Compound Synthetic Lethality Approach.

Authors:  Shiqi Xiao; Haidan Guo; Warren S Weiner; Clinton Maddox; Chunhong Mao; Hendra Gunosewoyo; Shaaretha Pelly; E Lucile White; Lynn Rasmussen; Frank J Schoenen; Jeffrey Aubé; William R Bishai; Shichun Lun
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

2.  Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).

Authors:  Andréanne Lupien; Anthony Vocat; Caroline Shi-Yan Foo; Emilyne Blattes; Jean-Yves Gillon; Vadim Makarov; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2018-10-24       Impact factor: 5.191

3.  Rational design of drug-like compounds targeting Mycobacterium marinum MelF protein.

Authors:  Renu Dharra; Sakshi Talwar; Yogesh Singh; Rani Gupta; Jeffrey D Cirillo; Amit K Pandey; Mahesh Kulharia; Promod K Mehta
Journal:  PLoS One       Date:  2017-09-05       Impact factor: 3.240

4.  Evaluation of Xpert®Mycobacterium tuberculosis/rifampin in sputum-smear negative and sputum-scarce patients with pulmonary tuberculosis using bronchoalveolar lavage fluid.

Authors:  Nikhil C Gowda; Animesh Ray; Manish Soneja; Arjun Khanna; Sanjeev Sinha
Journal:  Lung India       Date:  2018 Jul-Aug

5.  Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.

Authors:  Daniel L Clemens; Bai-Yu Lee; Aleidy Silva; Barbara Jane Dillon; Saša Masleša-Galić; Susana Nava; Xianting Ding; Chih-Ming Ho; Marcus A Horwitz
Journal:  PLoS One       Date:  2019-05-10       Impact factor: 3.240

6.  Microevolution of Mycobacterium tuberculosis Subpopulations and Heteroresistance in a Patient Receiving 27 Years of Tuberculosis Treatment in Germany.

Authors:  Stefan Niemann; Matthias Merker; Lindsay Sonnenkalb; Gerald Strohe; Viola Dreyer; Sönke Andres; Doris Hillemann; Florian P Maurer
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

7.  Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.

Authors:  María Pilar Arenaz-Callao; Rubén González Del Río; Ainhoa Lucía Quintana; Charles J Thompson; Alfonso Mendoza-Losana; Santiago Ramón-García
Journal:  PLoS Negl Trop Dis       Date:  2019-01-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.